Epstein-Barr, Antibodies (IgG) anti-EBNA. Screening

Clinical information

Diagnostic Utility:

This is the qualitative detection of IgG antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1), and its determination is useful in:

• Diagnosing infectious mononucleosis (IM).
• Determining the stage of EBV infection.

Method:

Chemiluminescence microparticle immunoassay (CMIA).

Reference Values

Possible results are: Reactive and Non-reactive.

Diagnostic Algorithm:

Not applicable.

Response Time:

Maximum 15 working days.

Specimen information

Sample: Serum and/or plasma
Tube: 1-5 mL aliquots, plasma tubes with EDTA, citrate or heparin as anticoagulants and/or serum tubes with or without gel separator.
Minimum essential volume: 1 ml
Stability:

• At room temperature: ≤ 3 days
• In refrigeration at 2-8 ºC: ≤ 14 days
• Sample frozen at or below -20ºC: 10 years

Transport instructions: Preferably at room temperature if they are whole blood tubes and refrigerated if they are serum and/or plasma aliquots.

Reason for rejection: Highly hemolyzed sample.

Administrative information

BST Code: 2110
Test Description: Epstein-Barr, Antibodies (IgG) anti-EBNA.
Synonyms: EBV EBNA-1 IgG
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates by clicking here.

Profiles:

Test 2110 Epstein-Barr, Antibodies (IgG) anti-EBNA Screening can be requested alone or with the profile:

References

• Inserts kits de EBV EBNA-1 IgG Architect, Abbott.